KB Financial Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

KB Financial Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$36K	Buy	205 +31	+18%	+$5.92K	0.01%	291
2023 Q2	$33K	Hold	174	–	–	0.01%	310
2023 Q1	$35K	Hold	174	–	–	0.01%	297
2022 Q4	$41K	Hold	174	–	–	0.01%	279
2022 Q3	$35K	Hold	174	–	–	0.01%	276
2022 Q2	$25K	Sell	174 -13	-7%	-$1.84K	0.01%	312
2022 Q1	$31K	Sell	187 -11	-6%	-$1.68K	0.01%	313
2021 Q4	$34K	Sell	198 -1,057	-84%	-$196K	0.01%	324
2021 Q3	$237K	Buy	1,255 +205	+20%	+$38.5K	0.09%	146
2021 Q2	$178K	Buy	+1,050	New	+$154K	0.07%	165

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

KB Financial Partners's ALNY Position: Q3 2023 in Review

KB Financial Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 18% in Q3 2023, buying an estimated $5.92K and bringing the position to 205 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #291.

KB Financial Partners first reported a position in ALNY in Q2 2021 and has held it in 10 quarters since. The position peaked at $237K in Q3 2021. 452 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

KB Financial Partners held 205 shares of Alnylam Pharmaceuticals worth $36K as of Q3 2023.
KB Financial Partners bought 31 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $5.92K.
Alnylam Pharmaceuticals made up 0.01% of KB Financial Partners's portfolio in Q3 2023, its #291 holding.
KB Financial Partners first reported a position in Alnylam Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
KB Financial Partners's Alnylam Pharmaceuticals position peaked at $237K in Q3 2021.
452 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on KB Financial Partners's 13F filing for Q3 2023, filed 15 Nov 2023.